Endometrial cancer is the most common gynaecologic malignancy and the fourth most common cancer among women in industrialised countries ([@bib41]). Although the prognosis is good, 15 to 20% of patients with presumed localised disease at diagnosis recur ([@bib1]; [@bib31]). Identifying biomarkers that can select patient populations for optimal surgical and systemic treatment is important to improve outcome for these patients.

The diagnosis and treatment of endometrial cancer patients usually consists of a preoperative biopsy followed by imaging, surgery and adjuvant treatment depending on risk classification. A complete surgical staging of endometrial cancer patients involves both pelvic and para-aortic lymphadenectomy ([@bib32]). Worldwide, there are however a wide variation in lymphadenectomy in endometrial cancer, and selection criteria for lymphadenectomy are not uniformly standardised ([@bib26], [@bib25]). Metastases to the lymph nodes are known to be associated with poor prognosis, and although lymphadenectomy provides diagnostic information that can help in selecting optimal adjuvant treatment, its effect on survival is uncertain, and it is associated with increased complication rates ([@bib5]; [@bib49]; [@bib30]). Improved identification of high-risk patients preoperatively is therefore needed to tailor the primary surgical strategy.

L1 cell adhesion molecule (L1CAM) is a cell adhesion molecule of the immunoglobulin superfamily ([@bib29]). It consists of an extracellular domain, a transmembrane region and a highly conserved cytoplasmic domain ([@bib29]). The extracellular domain of L1CAM can be cleaved by the metalloproteases ADAM10 and ADAM17, resulting in a soluble form of L1CAM ([@bib28]; [@bib27]). The L1CAM was initially identified in the nervous system and plays an important role in neurogenesis ([@bib33]; [@bib29]; [@bib36]). Later, L1CAM has also been shown to be involved in almost every aspect of cancer progression including promoting cell proliferation, migration, invasion and metastases of cancer cells ([@bib34]; [@bib36]; [@bib3]).

Expression of L1CAM has been investigated in several cancer types, and is associated with poor outcome ([@bib12]; [@bib2]; [@bib7]; [@bib37]; [@bib40]; [@bib44]; [@bib46]; [@bib17]). In endometrial cancer hysterectomy samples, L1CAM has been reported to be associated with aggressive disease characteristics including loss of hormone receptors and reduced survival ([@bib18]; [@bib51]; [@bib8]; [@bib9]; [@bib15]; [@bib45]; [@bib19]). The L1CAM is a strong prognostic marker within the subgroup of stage I endometrioid endometrial cancer ([@bib51]; [@bib45]), and within the subgroup of advanced-stage endometrioid endometrial cancer ([@bib45]), when evaluated postoperatively in hysterectomy samples. However, the expression of L1CAM in preoperative biopsies and its usefulness in preoperative prediction of lymph node metastases and outcome are not yet established. In addition, soluble L1CAM (sL1CAM) is suggested to be a valuable circulating biomarker in different cancers ([@bib50]; [@bib6]). It has been detected in the culture medium from different cell lines including melanoma, breast and ovarian cancer ([@bib4]; [@bib16]; [@bib24]), and also in serum and ascites of endometrial and ovarian cancer ([@bib12]; [@bib48]), suggesting that the soluble form of L1CAM may also play a role in these cancers.

The primary objective of this study was to assess the value of L1CAM in preoperative samples (curettage and plasma samples) as a predictive marker for lymph node metastases and poor prognosis. In addition, we aimed to validate the prognostic value of L1CAM in hysterectomy samples.

Materials and methods
=====================

Patient series
--------------

A population-based series was prospectively collected from 2001 to 2014 and included curettage specimen (*n*=600), primary tumours (*n*=795, of which 189 overlapped with cases published by [@bib45]) and plasma (*n*=372) from patients diagnosed with endometrial cancer in Hordaland County (Norway). Within the MoMaTEC study (Molecular markers in treatment of Endometrial Cancer, NCT00598845), nine other centres contributed with preoperative biopsies from in total 534 patients treated for endometrial cancer prospectively included at their institutions. Formalin-fixed, paraffin-embedded (FFPE) tumour tissue from curettage specimen was collected from all participating institutions ([@bib43]). Clinical and histopathological data were collected, including age, FIGO stage (according to 2009 criteria), histologic type and grade and myometrial invasion from hysterectomy specimen. Follow-up data were collected as previously described ([@bib42]). Preoperative histology reports were categorised as high risk (serous, clear cell, carcinosarcoma, undifferentiated carcinomas, endometrioid grade 3) or low risk (benign (diagnosed with endometrial cancer after hysterectomy), hyperplasia, endometrioid grades 1--2). Pelvic lymphadenectomy as part of surgical staging was conducted in the majority of cases (*n*=825, 73%); of these, additional para-aortic lymph node sampling was conducted for 6% (*n*=49). Fresh frozen tissue from hysterectomy samples was investigated for L1CAM mRNA expression in 232 patients, and these overlapped with FFPE samples.

The study has been approved by Norwegian legislation, including the Norwegian Data Inspectorate, Norwegian Social Science Data Services and the Western Regional Committee for Medical and Health Research Ethics (REK 2009/2315). All patients signed informed consent before inclusion in the study.

Immunohistochemical staining
----------------------------

The FFPE tissue from curettage and hysterectomy samples was available in tissue microarrays (TMAs) from 1134 and 795 patients, respectively, for evaluation of L1CAM level. The TMAs were generated from FFPE tissue as previously described, with three tissue cylinders from each case ([@bib39]). The TMAs were dewaxed in xylene and rehydrated in graded ethanol series before microwave boiling in target retrieval buffer (pH 9) for 15 min. The L1CAM was detected using purified anti-CD171 (L1) antibody clone 14.10 (Biolegend, San Diego, CA, USA) diluted 1 : 100 for 60 min at room temperature, followed by 30 min of incubation with secondary HPR-conjugated antibody. Diaminobenzidine was applied for 8 min before counterstaining with haematoxylin. All slides were scored independently and blinded for clinical and pathological data by two authors using standard light microscopy. Inter-evaluator *κ*-value was calculated to be 0.76 for L1CAM in two groups. The staining was evaluated as previously described ([@bib11]). Briefly, both intensity and area of positive tumour cells were considered. The intensity of staining was graded from 0 (no staining) to 3 (strong), and the area as 0, 1 (\<10%), 2 (10--50%) and 3 (51--100%). From this, a staining index (0--9) was calculated as the product of intensity and area. If heterogeneity was seen for the three tissue cylinders of each case, the three cylinders were given one overall averaged score. In subsequent statistical analysis indexes were grouped according to similarity in survival and considering the size of the subgroup and the number of events in each category. For L1CAM index 0--3 was considered low and 4--9 high ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). Immunohistochemical (IHC) staining and staining evaluation of ER and PR has previously been described ([@bib43]). Using the same scoring system as above, ER staining index ⩽3 and PR staining index 0 was defined as low expression/loss.

Enzyme-linked immunosorbent assay (ELISA)
-----------------------------------------

The EDTA-blood was obtained from 372 patients with endometrial cancer before primary surgery. The blood samples were centrifuged at 1600 **g** for 15 min and the plasma was stored at −80 °C until measurement of sL1CAM. The ELISA kits were bought from MyBioSource (Cat. No. MBS2023094, MyBioSource, San Diego, CA, USA) and the sandwich ELISA was performed according to the manufacturer's instructions. Briefly, 100 *μ*l plasma sample or standard was put into a 96-well microplate and incubated for 2 h at 37 °C. Then, 100 *μ*l biotin-conjugated L1CAM-specific antibody was added and incubated for 1 h at 37 °C. After the well was washed three times with washing solution, 100 *μ*l avidin conjugated to horseradish peroxidase (HRP) was added and incubated for 30 min at 37 °C. The wells were washed five times and 90 *μ*l substrate solution was added before 20 min of incubation away from light followed by addition of 50 *μ*l stop solution. The absorbance was measured in a microplate reader at the wavelength of 450 nm, and plasma concentration of sL1CAM calculated. For further statistical analysis the patients were grouped in four groups based on sL1CAM plasma level, and subsequently in high and low L1CAM based on similarities in survival (the three groups with lowest L1CAM level=low L1CAM level; the upper quartile=high L1CAM level) ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). Plasma from healthy age-matched female blood donors (*n*=32) was used as control group.

Gene expression analysis
------------------------

The RNA was extracted from fresh frozen tissue from primary tumour from patients diagnosed with endometrial cancer. Hybridisation to Agilent (Santa Clara, CA, USA) Whole Human Genome Microarray 44k (Cat. No. G4112F) was done according to the manufacturer's instructions. The arrays were scanned and normalised as previously described ([@bib21]).

Statistical analyses
--------------------

Data were analysed using SPSS version 24 (SPSS Inc., Chicago, IL, USA). Probability of \<0.05 was considered statistical significant, and all statistical tests were two sided. Associations between groups were analysed using the *χ*^2^ test for categorical variable and the Mann--Whitney *U*-test for continuous variables. Binary logistic regression was used to estimate odds ratios (ORs) for lymph node metastases. Univariate survival analysis was performed using the Kaplan--Meier (product-limit) method. Disease-specific survival was defined as time from surgery to death from endometrial cancer. Survival between groups was compared using the log-rank (Mantel--Cox) test. The Cox proportional hazard regression model was used to evaluate the prognostic impact of L1CAM adjusted for other prognostic parameters.

Results
=======

Expression of L1CAM in endometrial cancer curettage predicts lymph node metastases and poor outcome
---------------------------------------------------------------------------------------------------

The protein expression of L1CAM was evaluated by IHC in curettage samples from 1134 patients. Low expression was defined as staining index 0--3 and was found in 88% (*n*=1000) of the lesions, whereas 12% (*n*=134) expressed high levels of L1CAM. High L1CAM expression in curettage specimen was significantly associated with high age, loss of ER and PR expression and high-risk curettage classification and also high FIGO stage, non-endometrioid histology and high grade in the hysterectomy specimen (all *P*\<0.001) ([Table 1](#tbl1){ref-type="table"}). There was a highly significant correlation between L1CAM staining in curettage specimen and staining in the corresponding hysterectomy specimen (*P*\<0.001) ([Table 1](#tbl1){ref-type="table"}). High expression of L1CAM in curettage specimen predicted poor disease-specific survival, both in the whole patient population (*P*\<0.001) ([Figure 1A](#fig1){ref-type="fig"}) and within patients with low-risk curettage histology (*P*\<0.001) ([Figure 1B](#fig1){ref-type="fig"}). Expression of L1CAM also showed independent prognostic impact in Cox survival analysis after correction for age, FIGO stage, histologic subtype and grade assessed in the hysterectomy specimens, with hazard ratio of 1.77 (95% CI 1.17--2.66, *P*=0.006) ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}).

Interestingly, patients with high L1CAM expression in curettage specimen had significantly higher occurrence of lymph node metastases compared with patients with low expression of L1CAM, both in the whole patient population (33% *vs* 10% respectively, *P*\<0.001, [Table 1](#tbl1){ref-type="table"}) and in the subgroup with low-risk histology classification (30% *vs* 9% respectively, *P*\<0.001, [Supplementary Table 2](#sup1){ref-type="supplementary-material"}). In a univariate model, curettage high-risk histology, combined loss of ER/PR (a marker previously shown to be a strong predictor of lymph node metastases in endometrial cancer patients; [@bib43]) and high expression of L1CAM all predicted presence of metastatic lymph nodes ([Table 2](#tbl2){ref-type="table"}). When adjusting for curettage histology and preoperative ER/PR loss in a multivariate model, high expression of L1CAM predicted lymph node metastases with adjusted OR 2.51 (95% CI 1.41--4.64, *P*=0.002) ([Table 2](#tbl2){ref-type="table"}).

High sL1CAM level in preoperative blood samples is associated with lymph node metastases and poor survival in endometrial cancer patients
-----------------------------------------------------------------------------------------------------------------------------------------

The level of sL1CAM was also investigated in preoperative plasma samples from 372 patients with endometrial cancer. The plasma level of sL1CAM was significantly higher in endometrial cancer patients compared with healthy controls (*P*=0.001 (endometrial cancer patients: mean=997 pg ml^−1^, s.e.m.=27; healthy controls: mean=684 pg ml^−1^, s.e.m.=29)). There was a significant correlation between sL1CAM level in plasma evaluated by ELISA and L1CAM expression in both curettage specimen (*P*=0.007) ([Supplementary Figure 2A](#sup1){ref-type="supplementary-material"}) and hysterectomy specimen (*P*=0.015) ([Supplementary Figure 2B](#sup1){ref-type="supplementary-material"}) evaluated by IHC. High preoperative plasma levels of sL1CAM were significantly associated with high age, loss of ER and PR and high-risk histology in curettage, and also high FIGO stage and non-endometrioid histology in the hysterectomy specimen ([Table 3](#tbl3){ref-type="table"}). High sL1CAM plasma level predicted poor disease-specific survival in both the whole population (*P*\<0.001) ([Figure 1C](#fig1){ref-type="fig"}) and the group with low-risk curettage histology (*P*=0.04) ([Figure 1D](#fig1){ref-type="fig"}). sL1CAM level in plasma did not have independent prognostic impact when adjusting for age, FIGO stage, histologic type and grade (data not shown).

Patients with high sL1CAM plasma levels had significantly higher occurrence of lymph node metastases compared with patients with low sL1CAM level (23% *vs* 9% respectively, *P*=0.003) when including the whole patent population, but not within the subgroup with low-risk histology classification ([Supplementary Table 2](#sup1){ref-type="supplementary-material"}). In a univariate model both high-risk histology in curettage and high plasma levels of sL1CAM were predictive of lymph node metastases. In addition, when correcting for curettage histology in a multivariate model, sL1CAM level in plasma was a predictor of lymph node metastases with OR 2.25 (95% CI 1.01--5.02, *P*=0.048) ([Table 4](#tbl4){ref-type="table"}).

Expression of L1CAM in hysterectomy specimen validates to be a strong predictor of poor outcome in endometrial cancer
---------------------------------------------------------------------------------------------------------------------

Several studies have identified L1CAM as a strong prognostic marker when examining hysterectomy specimens in endometrial cancer. In this study we investigated expression of L1CAM in 795 primary tumours. In 14% of the cases (*n*=110), expression of L1CAM was high whereas 86% (*n*=685) of the cases showed low L1CAM levels. There was a significant association between L1CAM protein levels and L1CAM mRNA levels ([Supplementary Figure 3](#sup1){ref-type="supplementary-material"}). We identified that high expression of L1CAM in hysterectomy samples is associated with features of aggressive endometrial cancer ([Supplementary Table 3](#sup1){ref-type="supplementary-material"}) and poor survival ([Figure 1E](#fig1){ref-type="fig"}). Expression of L1CAM also showed independent prognostic impact in Cox survival analysis when adjusting for age, FIGO stage, histologic subtype and grade with HR 2.7 (95% CI 1.8--4.3, *P*\<0.001) ([Supplementary Table 4](#sup1){ref-type="supplementary-material"}). Within the subgroup of stage I endometrioid endometrial cancer, 5% of the cases expressed high L1CAM. In addition, within this subgroup, expression of L1CAM was associated with characteristics of aggressive endometrial cancer ([Supplementary Table 5](#sup1){ref-type="supplementary-material"}) and poor survival ([Figure 1F](#fig1){ref-type="fig"}), but it did not have independent prognostic impact when adjusting for age and histologic grade (data not shown).

Discussion
==========

There are several studies suggesting L1CAM as a promising biomarker in endometrial cancer, and its expression has earlier been shown to be associated with aggressive disease and poor survival, and inversely correlated with expression of ER and PR ([@bib18]; [@bib51]; [@bib8]; [@bib9]; [@bib15]; [@bib45]; [@bib19]). Current data point to an added prognostic value of L1CAM, and integrating L1CAM status as part of the molecular classification of endometrial cancer can be useful. We here validate that L1CAM is a strong prognostic marker in hysterectomy samples when including all samples in this prospectively collected population-based series. In addition, within the subgroup of patients with FIGO stage 1 endometrioid endometrial cancer, L1CAM expression is a predictor of poor survival, although not as strong as shown in other studies ([@bib51]; [@bib45]). The usefulness of L1CAM as a prognostic marker within this subgroup was also questioned in a recent study including 388 patients where L1CAM failed to be a clinically relevant marker of poor prognosis in FIGO stage 1 endometrioid endometrial cancer ([@bib38]). These differences could be explained by not only different scoring methods and cutoffs for L1CAM, but also differences in the patient cohort with regard to proportion of patients where lymphadenectomy is performed, as well as the use of adjuvant treatment.

In this study TMAs were used to determine the expression of L1CAM, and the staining index was used as scoring method with high expression defined as 4--9 and low expression defined as 0--3. Most other studies investigating the expression of L1CAM have used whole sections and a cutoff point of 10% ([@bib51]; [@bib8]; [@bib38]; [@bib45]). The use of different scoring methods and cutoffs make the studies less comparable; however, the fact that different scoring methods identify L1CAM as a strong biomarker supports its robustness as biomarker in endometrial cancer. Although an interobserver *κ*-value of 0.76 was obtained for L1CAM in this study, a scoring method like the staining index where both intensity and area are taken into account may be more subjectively influenced compared with the method only considering the area. Before potential clinical implementation of L1CAM as biomarker in endometrial cancer, the optimal staining protocol, scoring method and cutoff will have to be determined and validated. In an investigational setting the use of TMAs is both time and cost effective, and the method has been shown to yield reproducible results compared with full sections ([@bib20]; [@bib13]). However, TMAs do not provide the same morphological information as full sections, and should be used with caution, and depending on the research question. Although three tissue cores were used for each patient in this study, L1CAM-positive areas of the tumour might be missed that may result in underestimation of L1CAM expression. This is however also a challenge using full sections, and validation of markers is crucial before applied in a clinical setting.

In endometrial cancer the tumour is easily accessible for biopsy before surgery. Histologic type and grade are routinely investigated in the preoperative biopsies, and this provides prognostic information relevant for the extent of the surgery. However, the correlation between preoperative assessment of curettage and postoperative evaluation of hysterectomy specimens varies ([@bib22]; [@bib14]; [@bib10]; [@bib23]; [@bib47]). Therefore, identification of reliable markers in curettage material that could predict lymph node metastases would provide a better basis for treatment selection. There are different molecular markers that have been studied in preoperative biopsies, and could serve as predictive markers for metastatic disease ([@bib35]). One example is combined loss of ER and PR for prediction of lymph node metastases and poor survival in endometrial cancer ([@bib43]). Its usefulness in tailoring surgical treatment is currently tested in a clinical trial (Momatec2, NCT02543710), where the decision to perform lymphadenectomy in low- and intermediate-risk patients is dependent on the preoperative hormone receptor status. In the present study we investigate L1CAM level in curettage and preoperative blood samples, and its potential for predicting lymph node metastases and poor prognosis. Only few studies have previously investigated the expression of L1CAM in curettage samples. [@bib8]) compared expression of L1CAM in curettage and hysterectomy samples from 42 patients and [@bib12]) from 14 patients. Both studies reported a good concordance between staining in curettage and hysterectomy samples ([@bib12]; [@bib8]). We here confirm that the L1CAM staining in the curettage and hysterectomy sample is significantly associated. More importantly, we report the novel finding that high L1CAM expression in curettage samples is a significant predictor of lymph node metastases in both a univariate analysis and a multivariate analysis correcting for curettage histology and preoperative ER/PR expression. Our large study shows that L1CAM expression in curettage specimens is associated with features of aggressive endometrial cancer disease and poor survival in both the whole patient population and within the subgroup of patients with a preoperative low-risk histology classification. These findings suggest that evaluation of L1CAM in curettage samples could be a valuable supplement to the currently performed preoperative assessment for determination of surgical extent. However, this is the first study investigating L1CAM as a predictive marker for lymph node metastases and its prognostic impact in curettage specimens, and these findings would have to be validated in other studies before its place in the preoperative assessment can be determined.

The soluble form of L1CAM has earlier shown to be present in sera of endometrial cancer patients. In a study by [@bib12]), 9 out of 10 patients with L1CAM-positive endometrial tumours also had detectable concentrations of sL1CAM in preoperative serum samples. A recent study investigating serum levels of sL1CAM in 35 endometrial cancer patients found it to be lower in patients compared with healthy controls, and no correlations between soluble L1CAM concentration and histopathology, stage or grade were found ([@bib48]). The latter is contradictory to our results as we find that the level of sL1CAM is significantly increased in endometrial cancer patients compared with healthy controls, and that a high level of sL1CAM is associated with aggressive disease characteristics and poor survival. In addition, we report that a high level of sL1CAM in preoperative blood samples predicts lymph node metastasis in both a univariate analysis and a multivariate analysis correcting for preoperative histology. Increased level of sL1CAM has also been found to be associated with poor prognosis in other cancer types, such as in gastrointestinal stromal tumours ([@bib50]) and ovarian cancer ([@bib6]). Whether the soluble form of L1CAM, in addition to serving as a prognostic biomarker, also has a role in tumour development and progression is not clear, but studies investigating its function have suggested that sL1CAM is involved in stimulating cell motility and contributes to cell survival through activating anti-apoptotic pathways ([@bib28]; [@bib6]).

The primary treatment for endometrial cancer patients is surgical that typically includes hysterectomy and bilateral salpingo-oophorectomy with or without lymphadenectomy. Although lymphadenectomy is part of the complete staging procedure and important for risk stratification of endometrial cancer patients, no survival benefit is shown in randomised clinical trials, and it is associated with increased complication rates and prolonged operation time in a comorbid and obese patient population ([@bib5]; [@bib32]; [@bib49]; [@bib30]). Identifying markers that can preoperatively predict prognosis and lymph node metastases is important. Biomarkers can aid in tailoring the surgical treatment through identifying those patients with advanced disease who would benefit from extensive surgery, but also aid in preventing overtreatment in low-risk patients. Both L1CAM expression evaluated by IHC in curettage and the level of sL1CAM evaluated by ELISA in plasma seem to be promising biomarkers in endometrial cancer. Although L1CAM expression in curettage is a stronger predictor of both lymph node metastases and disease-specific survival in multivariate analysis compared with sL1CAM in plasma, and may be the preferred method, the fact that no tissue and only a blood sample is necessary for the sL1CAM analysis is an advantage. However, additional studies and in particular prospective randomised trials would be important to evaluate the effect of implementing L1CAM expression in curettage samples and sL1CAM level in blood samples into routine clinical practice.
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![**Expression of L1CAM is a prognostic marker in curettage samples, blood samples and hysterectomy samples of endometrial cancer patients.** High expression of L1CAM in curettage samples was significantly associated with poor outcome in the whole patient population (**A**) and in the subgroup of patients with low-risk histology in curettage (**B**). In plasma from endometrial cancer patients, high level of L1CAM was predictive of poor outcome in both the whole patient population (**C**) and the subgroup of patients with low-risk histology in curettage (**D**). High expression of L1CAM in hysterectomy samples is significantly associated with poor survival in both the whole population (**E**) and the subgroup with stage 1 endometrioid endometrial cancer (**F**). \*Curettage histological risk classification, low risk (benign, hyperplasia or endometrioid grades 1--2) or high risk (non-endometrioid or endometrioid grade 3). Number in brackets: number of patients in the group/number of events in the group.](bjc2017235f1){#fig1}

###### Clinicopathological variables related to L1CAM status in curettage specimens for women operated for endometrial cancer

                                                       **L1CAM**              
  ---------------------------------------------------- ----------- ---------- ---------
  **Age (years)**                                                             \<0.001
   \<66                                                520 (95)    30 (5)      
   ⩾66                                                 480 (82)    104 (18)    
  **Information available preoperatively**                                    
  **Curettage histology[a](#t1-fn3){ref-type="fn"}**                          \<0.001
   Low risk                                            811 (95)    40 (5)      
   High risk                                           170 (64)    94 (36)     
  **PR curettage**                                                            \<0.001
   Positive                                            795 (96)    36 (4)      
   Negative                                            191 (69)    88 (31)     
  **ER-*α* curettage**                                                        \<0.001
   Positive                                            746 (95)    43 (5)      
   Negative                                            228 (72)    89 (28)     
  **Information available postoperatively**                                   
  **FIGO-09 stage**                                                           \<0.001
   I--II                                               872 (91)    84 (9)      
   III--IV                                             128 (72)    50 (28)     
  **Histologic type**                                                         \<0.001
   Endometrioid                                        874 (96)    36 (4)      
   Adenosquamous                                       10 (91)     1 (9)       
   Clear cell                                          29 (71)     12 (29)     
   Serous papillary                                    39 (36)     70 (64)     
   Carcinosarcoma                                      35 (76)     11 (24)     
   Undifferentiated/other                              13 (77)     4 (23)      
  **Histologic grade[b](#t1-fn4){ref-type="fn"}**                             \<0.001
   Grade 1/2                                           754 (97)    21 (3)      
   Grade 3                                             120 (86)    19 (14)     
  **Metastatic nodes**                                                        \<0.001
   Negative                                            657 (92)    60 (8)      
   Positive                                            77 (72)     30 (28)     
  **Myometrial infiltration**                                                 \<0.001
   \<50%                                               608 (92)    51 (8)      
   ⩾50%                                                309 (84)    60 (16)     
  **Ploidy**                                                                  \<0.001
   Diploid                                             288 (94)    17 (6)      
   Aneuploid                                           49 (58)     35 (42)     
  **L1CAM hysterectomy specimen**                                             \<0.001
   Low                                                 431 (96)    16 (4)      
   High                                                26 (36)     46 (64)     

Abbreviations: ER=oestrogen receptor; FIGO=Federation of Gynaecology and Obstetrics; L1CAM=L1 cell adhesion molecule; PR=progesterone receptor.

Missing information on curettage histology classification for 19 patients, PR status in curettage for 24 patients, ER-*α* status in curettage for 28 patients, grade for 9 patients, metastatic nodes for 310 patients, myometrial infiltration for 106 patients, ploidy for 745 patients and L1CAM status in hysterectomy specimen for 615 patients.

Curettage histological risk classification, low risk (benign, hyperplasia or endometrioid grades 1--2) or high risk (non-endometrioid or endometrioid grade 3).

Only endometrioid.

###### Prediction of lymph node metastases based on curettage histology, status of L1CAM and ER/PR in curettage specimen in 763 lymph node sampled endometrial cancer patients

  **Variable**                                         ***N***[a](#t2-fn2){ref-type="fn"}   **Uni-variate OR**    **95% CI**  ***P***   **Multivariate OR**    **95% CI**  ***P***   **Sensitivity**   **Specificity**   **PPV**   **NPV**
  ---------------------------------------------------- ------------------------------------ -------------------- ------------ --------- --------------------- ------------ --------- ----------------- ----------------- --------- ---------
  **Curettage histology**[b](#t2-fn3){ref-type="fn"}                                                                                                                                                                               
  Low risk                                             590                                  1                                           1                                                                                           
  High risk                                            173                                  3.39                  2.19--5.23  \<0.001   1.94                   1.16--3.25  0.011     0.49              0.75              0.22      0.91
  **L1CAM expression**                                                                                                                                                                                                             
  Low                                                  681                                  1                                           1                                                                                           
  High                                                 82                                   4.49                  2.69--7.50  \<0.001   2.51                   1.41--4.64  0.002     0.28              0.92              0.33      0.90
  **ER/PR expression**                                                                                                                                                                                                             
  Normal                                               606                                  1                                           1                                                                                           
  Loss[c](#t2-fn4){ref-type="fn"}                      157                                  3.26                  2.10--5.07  \<0.001   1.91                   1.15--3.17  0.013     0.42              0.82              0.26      0.90

Abbreviations: CI=confidence interval; ER=oestrogen receptor; L1CAM=L1 cell adhesion molecule; NPV=negative predictive value; OR=odds ratio; PPV=positive predictive value; PR=progesterone receptor.

Only patients with data available for all variables included in the multivariate logistic regression analysis are included in the univariate analysis (*N*=763).

Curettage histological classification, low risk (benign, hyperplasia or endometrioid grades 1--2) or high risk (non-endometrioid or endometrioid grade 3).

Patients with double loss of ER/PR expression.

###### Clinicopathological variables related to sL1CAM status in preoperative blood samples from women treated for endometrial cancer

                                                       **sL1CAM**             
  ---------------------------------------------------- ------------ --------- ---------
  **Age (years)**                                                             \<0.001
   \<66                                                165 (89)     20 (11)    
   ⩾66                                                 116 (62)     71 (38)    
  **Information available preoperatively**                                    
  **Curettage histology[a](#t3-fn3){ref-type="fn"}**                          \<0.001
   Low risk                                            217 (80)     54 (20)    
   High risk                                           58 (62)      36 (38)    
  **PR curettage**                                                            0.027
   Positive                                            160 (81)     37 (20)    
   Negative                                            37 (67)      18 (33)    
  **ER-*α* curettage**                                                        0.023
   Positive                                            157 (81)     37 (19)    
   Negative                                            38 (67)      19 (33)    
  **Information available postoperatively**                                   
  **FIGO-09 stage**                                                           \<0.001
   I--II                                               252 (80)     61 (20)    
   III--IV                                             29 (49)      30 (51)    
  **Histologic type**                                                         \<0.001
   Endometrioid                                        238 (80)     61 (20)    
   Adenosquamous                                       4 (100)      0 (0)      
   Clear cell                                          9 (75)       3 (25)     
   Serous papillary                                    18 (55)      15 (45)    
   Carcinosarcoma                                      10 (59)      7 (41)     
   Undifferentiated/other                              2 (29)       5 (71)     
  **Histologic grade[b](#t3-fn4){ref-type="fn"}**                             0.95
   Grade 1/2                                           192 (80)     48 (20)    
   Grade 3                                             47 (80)      12 (20)    
  **Metastatic nodes**                                                        0.003
   Negative                                            225 (83)     44 (17)    
   Positive                                            22 (63)      13 (37)    
  **Myometrial infiltration**                                                 0.027
   \<50%                                               175 (80)     42 (20)    
   ⩾50%                                                106 (71)     44 (29)    
  **Ploidy**                                                                  0.15
   Diploid                                             145 (78)     42 (22)    
   Aneuploid                                           31 (67)      15 (33)    

Abbreviations: ER=oestrogen receptor; FIGO=Federation of Gynaecology and Obstetrics; PR=progesterone receptor; sL1CAM= soluble L1 cell adhesion molecule.

Missing information on curettage histology classification for 7 patients, PR status in curettage for 120 patients, ER-*α* status in curettage for 121 patients, grade for 4 patients, metastatic nodes for 68 patients, myometrial infiltration for 5 patients and ploidy for 139 patients.

Curettage histological risk classification, low risk (benign, hyperplasia or endometrioid grades 1--2) or high risk (non-endometrioid or endometrioid grade 3).

Only endometrioid.

###### Prediction of lymph node metastases based on curettage histology, and status for sL1CAM in preoperative blood samples in 299 lymph node sampled endometrial cancer patients

  **Variable**                                         ***N***[a](#t4-fn2){ref-type="fn"}   **Univariate OR**    **95% CI**   ***P***   **Multivariate OR**    **95% CI**   ***P***
  ---------------------------------------------------- ------------------------------------ ------------------- ------------- --------- --------------------- ------------- ---------
  **Curettage histology**[b](#t4-fn3){ref-type="fn"}                                                                                                                        
  Low risk                                             224                                  1                                           1                                    
  High risk                                            75                                   5.83                 2.79--12.22  \<0.001   5.21                   2.46--11.06  \<0.001
  **sL1CAM blood level**                                                                                                                                                    
  Low                                                  242                                  1                                           1                                    
  High                                                 57                                   2.96                 1.38--6.31   0.005     2.25                   1.01--5.02   0.048

Abbreviations: CI=confidence interval; OR=odds ratio; sL1CAM= soluble L1 cell adhesion molecule.

Only patients with data available for all variables included in the multivariate logistic regression analysis are included in the univariate analysis (*N*=299).

Curettage histological risk classification, low risk (benign, hyperplasia or endometrioid grades 1--2) or high risk (non-endometrioid or endometrioid grade 3).

[^1]: These authors contributed equally to this work.
